ClinicalTrials.gg
CompletedNCT01617434Updated Mar 8, 2017Results posted

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

A Phase 3 interventional study of liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 86 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-08.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
451
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
23rd of 151
451 · median 62
Started
2012
with 20 others
Phase 3
45 of 151
1 open now
Registered
64th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 23rd largest by enrollment, is one of 21 that started in 2012, is one of 45 in phase 3, and was the 64th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 451 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with type 2 diabetes for at least 180 days prior to screening and treated with stable basal insulin analogue dose of minimum 20 U/day with or without stable metformin equal to or above 1500 mg/day for at least 8 weeks prior to screening (defined as insulin adjustments less than 10% during the past 8 weeks as assessed by the investigator)
  • (glycosylated haemoglobin A1c) 7.0-10.0% (both inclusive)
  • (BMI) 20-45 kg/m\^2 (both inclusive)

Exclusion criteria

Exclusion Criteria:

  • Female of who is pregnant, breast-feeding or intending to become pregnant
  • Recurrent severe hypoglycaemic episodes or hypoglycaemic unawareness
  • Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria in a period of 12 weeks prior to screening
  • Impaired liver or renal function
  • Uncontrolled treated or untreated hypertension (systolic blood pressure (SBP) equal to or above 180 mmHg and/or diastolic blood pressure (DBP) equal to or above 100 mmHg)
  • Any disorder, except for conditions associated with type 2 diabetes history which in the investigator's opinion could interfere with results of the trial
  • Known or suspected abuse of alcohol or narcotics
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
451 participants (actual)

Study arms

  • Experimental
    Liraglutide

    Drug: liraglutide

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.

  • Drugplacebo

    Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26

    The estimated mean change from baseline in HbA1c after 26 weeks of treatment.

    Time frame: Week 0 to Week 26

Secondary outcomes

  1. Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26

    The estimated mean change from baseline in FPG after 26 weeks of treatment.

    Time frame: Week 0 to Week 26

  2. Change in Mean Self-Measured Plasma Glucose (SMPG) of 7-Point Profile From Baseline to Week 26

    The estimated mean change from baseline in mean SMPG of 7-point profile (7-points were before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime) after 26 weeks of treatment.

    Time frame: Week 0 to Week 26

  3. Change in Body Weight From Baseline to Week 26

    The estimated mean change in body weight after 26 weeks of treatment.

    Time frame: Week 0 to Week 26

  4. Number of Subjects Achieving HbA1c Below 7.0% (American Diabetes Association [ADA] Target)

    Number of subjects achieving HbA1c below 7.0% (American Diabetes Association \[ADA\] target) after 26 weeks of treatment

    Time frame: At Week 26

  5. Number of Subjects Achieving HbA1c Below or Equal to 6.5% (American Association of Clinical Endocrinologists [AACE] Target)

    Number of subjects achieving HbA1c below or equal to 6.5% (American Association of Clinical Endocrinologists \[AACE\] target) after 26 weeks of treatment.

    Time frame: At Week 26

  6. Number of Adverse Events (AEs) During The Randomised Treatment Period

    An AE was defined as treatment emergent if the onset date (or increase in severity) was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. The adverse events were categorised as 'serious' and 'non-serious' adverse events. Adverse events were also categorised according to the severity as 'mild', 'moderate' and 'severe' adverse events.

    Time frame: Week 0 to Week 26 + 7 days follow up

  7. Number of Minor Hypoglycaemic Episodes During The Randomised Treatment Period

    A minor hypoglycaemic episode was defined as either, (a) an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL) that was handled by the subject him/herself or (b) any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose value \<3.1 mmol/L (56 mg/dL).

    Time frame: Week 0 to Week 26 + 7 days follow up

  8. Number of Severe Hypoglycaemic Episodes During The Randomised Treatment Period

    Severe hypoglycaemia episode was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions.

    Time frame: Week 0 to Week 26 + 7 days follow up

08

Results

Posted Oct 28, 2014

Participant flow

The trial was conducted at 76 sites in 9 countries i.e. 3 sites in Argentina; 9 sites in Canada; 5 sites in Finland; 9 sites in Germany; 9 sites in India; 2 sites in Mexico; 7 sites in Netherlands; 3 sites in Serbia; 29 sites in United States.

Participant flow — Overall Study
MilestoneLiraglutidePlacebo
Started226225
Exposed225225
Completed191174
Not completed3551
Withdrew: Adverse event123
Withdrew: Protocol violation87
Withdrew: Withdrawal criteria1237
Withdrew: Unclassified34

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26

The estimated mean change from baseline in HbA1c after 26 weeks of treatment.

Time frame:
Week 0 to Week 26
Reported as:
Mean · percentage of glycosylated haemoglobin
Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26
percentage of glycosylated haemoglobinLiraglutidePlacebo
Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26-1.30 ± 1.015-0.11 ± 1.088
Statistical analysis
  • Liraglutide vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -1.19 · 95% CI -1.39 to -0.99
SecondaryChange in Fasting Plasma Glucose (FPG) From Baseline to Week 26

The estimated mean change from baseline in FPG after 26 weeks of treatment.

Time frame:
Week 0 to Week 26
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
mmol/LLiraglutidePlacebo
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26-1.44 ± 2.494-0.16 ± 3.006
Statistical analysis
  • Liraglutide vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -1.28 · 95% CI -1.70 to -0.86
SecondaryChange in Mean Self-Measured Plasma Glucose (SMPG) of 7-Point Profile From Baseline to Week 26

The estimated mean change from baseline in mean SMPG of 7-point profile (7-points were before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime) after 26 weeks of treatment.

Time frame:
Week 0 to Week 26
Reported as:
Mean · mmol/L
Change in Mean Self-Measured Plasma Glucose (SMPG) of 7-Point Profile From Baseline to Week 26
mmol/LLiraglutidePlacebo
Change in Mean Self-Measured Plasma Glucose (SMPG) of 7-Point Profile From Baseline to Week 26-2.61 ± 2.248-1.02 ± 3.061
Statistical analysis
  • Liraglutide vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -1.59 · 95% CI -2.01 to -1.18
SecondaryChange in Body Weight From Baseline to Week 26

The estimated mean change in body weight after 26 weeks of treatment.

Time frame:
Week 0 to Week 26
Reported as:
Mean · kg
Change in Body Weight From Baseline to Week 26
kgLiraglutidePlacebo
Change in Body Weight From Baseline to Week 26-3.54 ± 3.669-0.42 ± 3.909
Statistical analysis
  • Liraglutide vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -3.11 · 95% CI -3.85 to -2.37
SecondaryNumber of Subjects Achieving HbA1c Below 7.0% (American Diabetes Association [ADA] Target)

Number of subjects achieving HbA1c below 7.0% (American Diabetes Association \[ADA\] target) after 26 weeks of treatment

Time frame:
At Week 26
Reported as:
Number · percentage of subjects
Number of Subjects Achieving HbA1c Below 7.0% (American Diabetes Association [ADA] Target)
percentage of subjectsLiraglutidePlacebo
Number of Subjects Achieving HbA1c Below 7.0% (American Diabetes Association [ADA] Target)59.2414.02
Statistical analysis
  • Liraglutide vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 8.91 · 95% CI 5.45 to 14.59
SecondaryNumber of Subjects Achieving HbA1c Below or Equal to 6.5% (American Association of Clinical Endocrinologists [AACE] Target)

Number of subjects achieving HbA1c below or equal to 6.5% (American Association of Clinical Endocrinologists \[AACE\] target) after 26 weeks of treatment.

Time frame:
At Week 26
Reported as:
Number · percentage of subjects
Number of Subjects Achieving HbA1c Below or Equal to 6.5% (American Association of Clinical Endocrinologists [AACE] Target)
percentage of subjectsLiraglutidePlacebo
Number of Subjects Achieving HbA1c Below or Equal to 6.5% (American Association of Clinical Endocrinologists [AACE] Target)42.913.60
Statistical analysis
  • Liraglutide vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 20.12 · 95% CI 9.92 to 40.84
SecondaryNumber of Adverse Events (AEs) During The Randomised Treatment Period

An AE was defined as treatment emergent if the onset date (or increase in severity) was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. The adverse events were categorised as 'serious' and 'non-serious' adverse events. Adverse events were also categorised according to the severity as 'mild', 'moderate' and 'severe' adverse events.

Time frame:
Week 0 to Week 26 + 7 days follow up
Reported as:
Number · Events/1000 years of patient exposure
Number of Adverse Events (AEs) During The Randomised Treatment Period
Events/1000 years of patient exposureLiraglutidePlacebo
Adverse Events49183737
Serious Adverse Events149101
Severe Adverse Events169101
Moderate Adverse Events12741060
Mild Adverse Events34742575
SecondaryNumber of Minor Hypoglycaemic Episodes During The Randomised Treatment Period

A minor hypoglycaemic episode was defined as either, (a) an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL) that was handled by the subject him/herself or (b) any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose value \<3.1 mmol/L (56 mg/dL).

Time frame:
Week 0 to Week 26 + 7 days follow up
Reported as:
Number · Events/100 years of patient exposure
Number of Minor Hypoglycaemic Episodes During The Randomised Treatment Period
Events/100 years of patient exposureLiraglutidePlacebo
Number of Minor Hypoglycaemic Episodes During The Randomised Treatment Period12683
SecondaryNumber of Severe Hypoglycaemic Episodes During The Randomised Treatment Period

Severe hypoglycaemia episode was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions.

Time frame:
Week 0 to Week 26 + 7 days follow up
Reported as:
Number · Events/100 years of patient exposure
Number of Severe Hypoglycaemic Episodes During The Randomised Treatment Period
Events/100 years of patient exposureLiraglutidePlacebo
Number of Severe Hypoglycaemic Episodes During The Randomised Treatment Period00

Adverse events

Collected over Week 0 to Week 26 + 7 days follow up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide—11/225 (4.9%)103/225 (45.8%)
Placebo—7/225 (3.1%)46/225 (20.4%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventLiraglutidePlacebo
Coronary artery diseaseCardiac disorders0/2252/225
Acute myocardial infarctionCardiac disorders1/2250/225
IleusGastrointestinal disorders1/2250/225
Arthritis bacterialInfections and infestations0/2251/225
Cellulitis staphylococcalInfections and infestations1/2250/225
Ear infectionInfections and infestations1/2250/225
GastroenteritisInfections and infestations1/2250/225
Genital herpesInfections and infestations1/2250/225
OsteomyelitisInfections and infestations0/2251/225
PneumoniaInfections and infestations1/2250/225
Most frequent other events
Most frequent other events
EventLiraglutidePlacebo
NauseaGastrointestinal disorders50/2257/225
DiarrhoeaGastrointestinal disorders24/22511/225
Decreased appetiteMetabolism and nutrition disorders22/2255/225
VomitingGastrointestinal disorders20/2252/225
DyspepsiaGastrointestinal disorders16/2252/225
InfluenzaInfections and infestations8/22516/225
Lipase increasedInvestigations16/2255/225
HeadacheNervous system disorders8/22516/225
NasopharyngitisInfections and infestations13/22514/225
Back painMusculoskeletal and connective tissue disorders12/22512/225

Baseline characteristics

Age, Continuous
Age, Continuous(years)LiraglutidePlaceboTotal
Mean59.3 ± 9.257.5 ± 11.158.4 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)LiraglutidePlaceboTotal
Female10589194
Male120136256
Body Weight
Body Weight(kg)LiraglutidePlaceboTotal
Mean90.23 ± 19.9891.85 ± 21.3391.04 ± 20.66
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mmol/L)LiraglutidePlaceboTotal
Mean8.32 ± 2.898.21 ± 2.908.27 ± 2.89
Glycosylated Haemoglobin (HbA1c)
Glycosylated Haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)LiraglutidePlaceboTotal
Mean8.22 ± 0.818.28 ± 0.908.25 ± 0.86
09

Study locations

86 sites
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85020, United States
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93726, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90057, United States
  • Novo Nordisk Investigational Site
    San Mateo, California 94401, United States
  • Novo Nordisk Investigational Site
    San Ramon, California 94583, United States
  • Novo Nordisk Investigational Site
    Tustin, California 92780-7045, United States
  • Novo Nordisk Investigational Site
    Ventura, California 93003, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Kissimmee, Florida 34741, United States
  • Novo Nordisk Investigational Site
    Gurnee, Illinois 60031, United States
  • Novo Nordisk Investigational Site
    Greenfield, Indiana 46140, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Metairie, Louisiana 70002, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Methuen, Massachusetts 01844, United States
  • Novo Nordisk Investigational Site
    Omaha, Nebraska 68114, United States
  • Novo Nordisk Investigational Site
    Newington, New Hampshire 03801, United States
  • Novo Nordisk Investigational Site
    Greensboro, North Carolina 27401-1023, United States
  • Novo Nordisk Investigational Site
    McMurray, Pennsylvania 15317, United States
  • Novo Nordisk Investigational Site
    Spartanburg, South Carolina 29303, United States
  • Novo Nordisk Investigational Site
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78215, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78224, United States
  • Novo Nordisk Investigational Site
    Sugarland, Texas 77478, United States
  • Novo Nordisk Investigational Site
    Salt Lake City, Utah 84107, United States
  • Novo Nordisk Investigational Site
    Midlothian, Virginia 23114, United States
  • Novo Nordisk Investigational Site
    Richmond, Virginia 23219, United States
  • Novo Nordisk Investigational Site
    Renton, Washington 98057, United States
  • Novo Nordisk Investigational Site
    Martinsburg, West Virginia 25401, United States
  • Novo Nordisk Investigational Site
    Buenos Aires, C1425AGC, Argentina
  • Novo Nordisk Investigational Site
    Caba, C1179AAB, Argentina
  • Novo Nordisk Investigational Site
    Caba, C1180AAX, Argentina
  • Novo Nordisk Investigational Site
    Córdoba, X5016KEH, Argentina
  • Novo Nordisk Investigational Site
    Coquitlam, British Columbia V3K 3P4, Canada
  • Novo Nordisk Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novo Nordisk Investigational Site
    Burlington, Ontario L7M 4Y1, Canada
  • Novo Nordisk Investigational Site
    Hamilton, Ontario L8M 1K7, Canada
  • Novo Nordisk Investigational Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Novo Nordisk Investigational Site
    Mississauga, Ontario L5M 2V8, Canada
  • Novo Nordisk Investigational Site
    Ottawa, Ontario K1K 4L2, Canada
  • Novo Nordisk Investigational Site
    Smiths Falls, Ontario K7A 4W8, Canada
  • Novo Nordisk Investigational Site
    Thunder Bay, Ontario P7A 4V7, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M3J 1N2, Canada
  • Novo Nordisk Investigational Site
    Westmount, Quebec H3Z 1E5, Canada
  • Novo Nordisk Investigational Site
    Helsinki, FI-00100, Finland
  • Novo Nordisk Investigational Site
    Kerava, FI-04200, Finland
  • Novo Nordisk Investigational Site
    Tampere, 33520, Finland
  • Novo Nordisk Investigational Site
    Turku, FI-20520, Finland
  • Novo Nordisk Investigational Site
    Ylitornio, FI-95600, Finland
  • Novo Nordisk Investigational Site
    Aschaffenburg, 63739, Germany
  • Novo Nordisk Investigational Site
    Bad Lauterberg, 37431, Germany
  • Novo Nordisk Investigational Site
    Berlin, 10117, Germany
  • Novo Nordisk Investigational Site
    Berlin, 13055, Germany
  • Novo Nordisk Investigational Site
    Friedrichsthal, 66299, Germany
  • Novo Nordisk Investigational Site
    Gelnhausen, 63571, Germany
  • Novo Nordisk Investigational Site
    Gifhorn, 38518, Germany
  • Novo Nordisk Investigational Site
    Hohenmölsen, 06679, Germany
  • Novo Nordisk Investigational Site
    Mannheim, 68163, Germany
  • Novo Nordisk Investigational Site
    Mayen, 56727, Germany
  • Novo Nordisk Investigational Site
    Oldenburg, 23758, Germany
  • Novo Nordisk Investigational Site
    Visakhapatnam, Andhra Pradesh 530002, India
  • Novo Nordisk Investigational Site
    Rohtak, Haryana 124001, India
  • Novo Nordisk Investigational Site
    Bangalore, Karnataka 560034, India
  • Novo Nordisk Investigational Site
    Indore, Madhya Pradesh 452010, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400012, India
  • Novo Nordisk Investigational Site
    Jaipur, Rajasthan 302006, India
  • Novo Nordisk Investigational Site
    Kolkatta, West Bengal 700031, India
  • Novo Nordisk Investigational Site
    Hyderabad, 600034, India
  • Novo Nordisk Investigational Site
    Kolkata, 700017, India
  • Novo Nordisk Investigational Site
    Thriruvananthapuram, 695 032, India
  • Novo Nordisk Investigational Site
    Pachuca, Hidalgo 42084, Mexico
  • Novo Nordisk Investigational Site
    Mexico, D.F., México, D.F. 03800, Mexico
  • Novo Nordisk Investigational Site
    Almere, 1315 RA, Netherlands
  • Novo Nordisk Investigational Site
    Breda, 4811 SW, Netherlands
  • Novo Nordisk Investigational Site
    Eindhoven, 5616 GB, Netherlands
  • Novo Nordisk Investigational Site
    Groningen, 9728 NT, Netherlands
  • Novo Nordisk Investigational Site
    Hoogeveen, 7909 AA, Netherlands
  • Novo Nordisk Investigational Site
    Leiden, 2333 ZA, Netherlands
  • Novo Nordisk Investigational Site
    Rotterdam, 3021 HC, Netherlands
  • Novo Nordisk Investigational Site
    Velp, 6883 ES, Netherlands
  • Novo Nordisk Investigational Site
    Venlo, 5912 BL, Netherlands
  • Novo Nordisk Investigational Site
    Zoetermeer, 2724 EK, Netherlands
  • Novo Nordisk Investigational Site
    Zwijndrecht, 3331 LZ, Netherlands
  • Novo Nordisk Investigational Site
    Nis, 18000, Serbia
10

References and documents

Publications

  • Ahmann A, Rodbard HW, Rosenstock J, Lahtela JT, de Loredo L, Tornoe K, Boopalan A, Nauck MA; NN2211-3917 Study Group. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2015 Nov;17(11):1056-64. doi: 10.1111/dom.12539. Epub 2015 Sep 10. PubMed 26179619 ↗
  • Freemantle N, Mamdani M, Vilsboll T, Kongso JH, Kvist K, Bain SC. IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy. Diabetes Ther. 2015 Dec;6(4):573-591. doi: 10.1007/s13300-015-0142-y. Epub 2015 Nov 18. PubMed 26582052 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2012
First posted
Jun 12, 2012
Start
Sep 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Oct 28, 2014
Last update
Mar 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01617434
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 12, 2012
Start date
Sep 2012
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Oct 28, 2014
Last update
Mar 8, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion